Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia

Blood

Volumn 95, Issue 4, 2000, Pages 1124-1129

  De Jonge, Evert ^a   Dekkers, Pascale E P ^b   Creasey, Abla A ^b   Hack, C Erik ^b   Paulson, Susan K ^b   Karim, Aziz ^b   Kesecioglu, Jozef ^b   Levi, Marcel ^b   Van Deventer, Sander J H ^b   Van Der Poll, Tom ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE RELEASE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENDOTOXEMIA; FIBRINOLYSIS; GRAM NEGATIVE SEPSIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 18844480902     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1124.002k20_1124_1129     Document Type: Article

References (52)

1. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992;101:816-823.
2. de Jonge E, Levi M, Stoutenbeek CP, van Deventer SJ. Current drug treatment strategies for disseminated intravascular coagulation. Drugs. 1998;55:767-777.
3. Ryan J, Brett J, Tijburg P, Bach RR, Kisiel W, Stern D. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood. 1992;80:966-974.
4. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998;91:4216-4223.
5. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134:1087-1097.
6. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 1989;86:2839-2843.
7. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost. 1983;49:5-7.
8. Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol. 1975;30:311-316.
9. Moldow CF, Bach RR, Staskus K, Rick PD. Induction of endothelial tissue factor by endotoxin and its precursors. Thromb Haemost. 1993;70:702-706.
10. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MAJr: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A. 1986;83:4533-4537.
11. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986;163:740-745.
12. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994;93:114-120.
13. Taylor FB Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991; 33:127-134.
14. Biemond BJ, Levi M, ten Cate H, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost. 1995;73:223-230.
15. Taylor FB, Chang ACK, Peer G, Li A, Ezban M Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood. 1998;91:1609-1615.
16. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91:2850-2856.
17. Carr C, Bild GS, Chang AC, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock. 1994;44:126-137.
18. Randolph MM, White GL, Kosanke SD, et al. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli, a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli. Thromb Haemost. 1998;79: 1048-1053.
19. Taylor FB Jr, Chang AC, Peer GT, et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood. 1991;78: 364-368.
20. Taylor FB Jr. Tissue factor and thrombin in posttraumatic systemic inflammatory response syndrome. Crit Care Med. 1997;25:1774-1775.
21. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation [abstract]. Blood Coagul Fibrinolysis. 1995:6(suppl 1):S7-S13.
22. Goldfarb RD, Glock D, Johnson K, et al. Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Shock. 1998;10:258-264.
23. Camerota AJ, Creasey AA, Patla V, Larkin VA, Fink MP. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis. J Infect Dis. 1998;177:668-676.
24. van der Poll T, Jansen J, van Leenen D, et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis. 1993;168:955-960.
25. Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood. 1997;89:3270-3276.
26. Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest. 1996;75: 281-289.
27. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 1989:338:518-520.
28. Valentin S, Nordfang O, Bregengard C, Wildgoose P: Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis 4:713-720, 1993.
29. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem. 1989;264:18,832-18,837.
30. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood. 1988:72: 2020-2025.
31. Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood. 1992;79:3219-3226.
32. Lindahl AK. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res. 1997;33:286-291.
33. Takahashi H, Sato N, Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor. Thromb Res. 1995;80:339-348.
34. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991;78:387-393.
35. Sandset PM, Roise O, Aasen AO, Abildgaard U. Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. Haemostasis. 1989;19:189-195.
36. Sabharwal AK, Bajaj SP, Ameri A, et al. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model ot sepsis. Am J Resp Crit Care Med. 1995;151:758-767.
37. Gralnick HR, McKeown LP, Wilson OM, Williams SB, Elin RJ. von Willebrand factor release induced by endotoxin. J Lab Clin Med. 1989;113: 118-122.
38. Wyshock EG, Suffredini AF, Parrillo JE, Colman RW. Cofactors V and VIII after endotoxin administration to human volunteers. Thromb Res. 1995; 80:377-389.
39. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76:2520-2526.
40. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects [see comments]. N Engl J Med. 1989;320:1165-1172.
41. Biemond BJ, Levi M, ten Cate H, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci. 1995; 88:587-594.
42. van der Poll T, Levi M, van Deventer SJ, et al. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood. 1994;83:446-451.
43. van der Poll T, Coyle SM, Levi M, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. 1997;89:3727-3734.
44. De la Cadena R, Majluf-Cruz A, Stadnicki A, et al. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemost. 1998;80:114-118.
45. Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood. 1997;89:4393-4401.
46. Johnson K, Aarden L, Choi Y. De Groot E, Creasey A. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood. 1996;87:5051-5060.
47. Qi J, Goralnick S, Kreutzer DL. Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. Blood. 1997;90:3595-3602.
48. Anrather D, Millan MT, Palmetshofer A, et al. Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF. J Immunol. 1997;159:5620-5628.
49. Sower LE, Froelich CJ, Carney DH, Fenton JW, Kumpel GR. Thrombin induces IL-6 production in fibroblasts and epithelial cells: evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol. 1995;155:895-901.
50. Senden NHM, Jeunhomme TMAA, Heemskerk JWM, et al. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol. 1998;161:4318-4324.
51. Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood. 1997;89:4268-4274.
52. Hooper WC, Phillips DJ, Renshaw MA, Evatt BL, Benson JM. The up-regulation of IL-6 and IL-8 in human endothelial cells by activated protein C. J Immunol. 1998;161:2567-2573.